Regimex (Benzphetamine) is indicated for use as a short-term pharmacological aid strictly within the therapeutic domain of exogenous obesity in adults. Its role is to provide supportive relief when symptoms of uncontrolled appetite interfere with routine activities and where additional symptomatic support may be needed.

---

The medication is commonly used to help with the primary symptom of excessive appetite and the lack of satiety. It is applied across conditions presenting with significant overweight, including patients who meet clinical classifications for obesity or those who have concurrent weight-related conditions like hypertension or diabetes. This drug is generally intended for use as a supplement to a comprehensive weight management regimen that includes diet, exercise, and behavioral modification.

The drug contributes to easing the overall symptom load associated with adhering to a caloric restriction diet.

This supportive benefit helps patients cope more steadily with the challenging process of caloric restriction, assisting with maintaining functional stability during the initial phase of weight management.

---

Quick Fact: Relief for Excessive Appetite
Regimex is relevant for easing symptoms related to heightened physiological activity and is applied in scenarios where additional management of uncontrolled hunger is appropriate.

Regulatory References

1. DailyMed NLM Drug Label

Regimex (benzphetamine hydrochloride) is officially approved for adults diagnosed with exogenous obesity as a short-term adjunct to a comprehensive regimen involving caloric restriction and exercise. This limited scope of use is reinforced by numerous regulatory exclusions.

The medication is contraindicated in patients with a wide range of pre-existing medical conditions, including advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, hyperthyroidism, and glaucoma. It must also be avoided by individuals with a history of drug abuse or those currently in an agitated state. Use is absolutely prohibited in women who are or may become pregnant, and lactating mothers are advised to refrain from nursing. Furthermore, Regimex must not be taken concurrently with Monoamine Oxidase Inhibitors (MAOIs) or other CNS stimulants.

Regarding age, safety and effectiveness have not been established in pediatric patients, and use is not recommended for individuals under 12 years of age. Caution is required when prescribing to the elderly due to the higher likelihood of age-related organ issues. Treatment is conditional: the drug must be discontinued if a patient does not achieve satisfactory weight loss within the initial four weeks.

Interactions with other medicines and products

The interaction profile of Regimex (Benzphetamine) is defined by its classification as a sympathomimetic amine, leading to documented restrictions with other centrally acting agents and medicines that modify its clearance.

Contraindicated Combinations

The following combinations are formally prohibited in regulatory labeling due to the risk of severe pharmacodynamic interactions, such as hypertensive crisis:

• Monoamine Oxidase Inhibitors (MAOIs): Co-administration is strictly contraindicated. Regimex must not be used within 14 days of stopping an MAOI.
• Other Sympathomimetic Agents or Anorectics: Co-administration with other appetite suppressants, including prescribed medications and certain herbal products, is prohibited due to additive effects.

Pharmacokinetic and Pharmacodynamic Interactions

Interactions that alter the drug's systemic exposure and duration of action are primarily based on changes to urinary pH. Alkalinizing agents (e.g., Sodium Bicarbonate) officially increase blood concentrations of the active component by reducing renal excretion. Conversely, acidifying agents lead to decreased exposure and a shorter duration of action.

In pharmacodynamic terms, Regimex may counteract the blood pressure-lowering effect of certain Antihypertensive Agents (e.g., Guanethidine). Conversely, Tricyclic Antidepressants (TCAs) may officially enhance the CNS stimulant effects of Regimex.

Regimex (benzphetamine) functions as a sympathomimetic amine primarily targeting the Central Nervous System (CNS). Its molecular action involves binding to the Vesicular Monoamine Transporter 2 (VMAT2) as an inducer, and inhibiting the Sodium-dependent Dopamine Transporter.

This interaction promotes the non-exocytotic release of norepinephrine and dopamine from presynaptic nerve terminals, increasing their concentration in the synaptic cleft. The resultant higher extracellular monoamine levels lead to persistent agonist activity at postsynaptic G-protein-coupled receptors, including alpha-1A and alpha-2A adrenergic receptors, and D-type dopamine receptors, particularly within the lateral hypothalamic feeding center.

This cellular signaling modulation alters neuronal excitability and activity in key appetite regulation circuits. Concurrently, the systemic increase in norepinephrine signaling mediates peripheral vasoconstriction and elevated chronotropic and inotropic cardiac effects, contributing to a system-level rise in blood pressure and heart rate.

The administration of Regimex (Benzphetamine hydrochloride) is determined by established guidelines, prescribing a framework for its use as a short-term measure.

General Administration Guidelines

Parameter	General Instruction
Route of Administration	The drug is available as a tablet for oral administration.
Dosing Schedule (Adults)	Starting Dose: 25 mg to 50 mg once daily. Maintenance Dose: 25 mg to 50 mg per dose, adjustable up to three times daily (TID).
Timing Constraint	Dosing should be administered in the mid-morning or mid-afternoon to prevent sleep disruption; late afternoon administration should be avoided.
Preparation	No special preparation steps, such as dilution or reconstitution, are required.

Procedural and Time-Based Rules

Age-Group Administration Rules: The drug is not recommended for individuals under 12 years of age. For older adults, dosing should proceed with caution, typically initiating at the lower end of the adult dosing range.

Duration and Discontinuation: The drug is intended for use as a short-term adjunct only, generally for a few weeks. Continuation of treatment beyond the first four weeks is contingent upon achieving satisfactory weight loss. If a patient develops tolerance to the effects, the dose must not be increased; the drug should be discontinued.

Missed Dose: If a dose is missed, it should be taken as soon as remembered; however, if it is almost time for the next scheduled dose, the missed dose should be skipped to avoid taking a double dose.

These parameters define a protocol where administration is time-sensitive, dose-limited, and contingent on early patient response, governing the standardized use of Regimex.

Research evidence / Overview of studies for Regimex

Regimex was studied for various conditions characterized by fluctuating or episodic manifestations. Research explored how symptoms related to physical discomfort and changes in daily functioning were measured in the study settings. The findings from these studies help show what has been observed so far, but it is important to remember that research provides context but not individual predictions. The evidence highlights what is known—and what is still uncertain—about the patterns observed during the study periods.

---

Symptom Complex A

Research was observed in contexts involving individuals with Symptom Complex A. These studies conducted during periods of increased symptom activity explored how outcomes related to physical discomfort and intensity changed over a defined time interval.

Adult Population Studies

The evidence was studied for adult populations across several trials. These studies explored how symptoms evolved in the observed populations, and findings describe patterns observed in the studies. Specifically, patterns related to symptom intensity were monitored in studies involving Regimex. Further, patterns of physical discomfort were observed in the study period for a proportion of the study participants. However, it is essential to note that follow-up durations were limited in many of these settings. While the research provides insight into short-term changes, the long-term effects are not fully established beyond the short-term follow-up.

Subgroup Findings for Symptom Complex A

Regimex was evaluated in a small number of studies that focused on specific subgroups of patients with Symptom Complex A, particularly those with conditions involving periods of heightened symptoms. Research examined a limited number of participants with this specific pattern. Findings were mixed across these smaller studies. For example, some studies monitored patient-reported outcomes describing perceived discomfort and showed patterns related to the frequency of acute episodes, while others did not report this observation. Since the sample sizes were modest in these studies and subgroup findings are uncertain, the data for certain groups remain insufficient to draw broad conclusions.

---

Symptom Pattern B

Regimex was studied for conditions associated with acute or disruptive episodes, which are relevant in trials assessing short-term or episodic symptom patterns. The research examined patterns related to episodic or acute changes and outcomes related to systemic or functional imbalance.

Initial Research Findings

Initial research monitored patients with Symptom Pattern B in short-term studies. These studies explored how symptoms changed over time, specifically focusing on phases of heightened symptom activity. Data show patterns related to the frequency of these episodes in the observed populations. However, it is important to remember that the evidence quality varies across studies, and the studies report how symptoms evolved only in the observed populations. At this time, data are still emerging, and comparative evidence is lacking for how this pattern compares to other available approaches. The results apply only to the populations studied, and the evidence contributes to understanding symptom patterns rather than offering definitive conclusions.

Long-Term Monitoring

Long-term effects are not fully established for Symptom Pattern B. Evidence is limited regarding extended-term observations, as follow-up durations were limited in the primary trials. Observational settings evaluating daily-life functioning have been applied in studies examining the continued functional imbalance, but data for certain groups remain insufficient, especially when looking for outcomes related to long-term stability and function. Research is ongoing in settings examining this specific symptom pattern.

Common questions about Regimex (FAQ)

Q: Does Regimex start working right away, or does it take a few weeks?

Regimex is understood to have a relatively quick effect after taking a dose. Official pharmacokinetic data indicates that the active component's elimination half-life, which relates to how long it stays active in the body, is typically between 4 and 6 hours. This information is consistent with a relatively quick onset and limited duration of effect for each dose.

Q: Are there any common foods or drinks that should be avoided when taking Regimex?

Official regulatory guidance describes the risk of using alcohol while taking Regimex. This is because combining the two can increase the risk of developing serious cardiovascular and nervous system side effects. The official product information does not specify restrictions for common foods.

Q: Why do some people say they felt tired when they first started taking Regimex?

Although Regimex is a stimulant, official safety documents list insomnia (difficulty sleeping) as a reported side effect affecting the nervous system. The fatigue or tiredness some people report may be indirectly related to the disturbance of their normal sleep patterns caused by this stimulating effect.

Q: Is Regimex known to interact with herbal supplements like St. John's Wort?

The official label strictly contraindicates (prohibits) taking Regimex with other sympathomimetic agents or appetite suppressants. This warning is very broad and may apply to certain herbal products that have stimulating or appetite-reducing effects. Regulatory documents do not list St. John's Wort by name.

Q: What is the general duration of effect for a single dose of Regimex?

The general duration of effect for a single dose is tied to its metabolism in the body. According to regulatory-referenced pharmacokinetic data, the active component of Regimex has an elimination half-life of approximately 4 to 6 hours.

Q: Are there any specific tests that doctors use to monitor safety while a person is on Regimex?

Official information states that baseline cardiac evaluation—potentially including an echocardiogram—may be advised as a screening step before a person starts Regimex. This helps screen for pre-existing heart valve issues. Blood and blood pressure tests are also recommended to check for unwanted effects during treatment.

Q: What does the patient information leaflet say about stopping Regimex?

Official information describes that abrupt discontinuation is not advised due to potential withdrawal effects. The documented process for stopping the drug involves gradually reducing the dose under medical supervision.

Q: Are there any known common interactions between Regimex and alcohol?

Yes, official safety labeling describes the heightened risk when combining Regimex and alcohol. This combination can significantly increase the risk of serious side effects, particularly those affecting the heart and blood vessels (cardiovascular system) and the nervous system (CNS).

Q: Does Regimex have a generic version available?

The FDA has reviewed the history of the original brand-name product (Didrex) and determined that it was not withdrawn from the market for reasons related to its safety or effectiveness. This regulatory status allows for the potential approval of generic versions containing the active ingredient, Benzphetamine Hydrochloride.

Q: What is the primary reason why Regimex is not used by pregnant people?

Use during pregnancy is contraindicated (prohibited) based on its mechanism and findings from animal studies. Official information indicates that the drug may cause fetal harm.

Q: Is it possible to be allergic to an ingredient in Regimex?

The official safety profile lists urticaria (hives) and other allergic reactions involving the skin as documented adverse effects. It is also contraindicated for anyone with a known hypersensitivity (severe allergic reaction) to sympathomimetic amines.

Q: Does Regimex affect the ability to drive or operate machinery?

The patient information cautions that this medication may impair a person's ability to engage in potentially hazardous activities such as operating machinery or driving a motor vehicle. This is due to its effects on the central nervous system.

Q: What happens in the body if too much Regimex is taken?

Regulatory documents warn that an overdose can be fatal. Symptoms reported may include effects on the nervous system (confusion, panic, aggressive behavior, seizures) and the cardiovascular system (dangerously high blood pressure and irregular heartbeat).

Q: What kind of studies confirm the main use of Regimex?

The indication for its use as a short-term adjunct for exogenous obesity is supported by relatively short-term clinical trials. These studies indicated that subjects treated with the drug plus diet lost more weight on average than those treated with placebo and diet.

Q: Is there a high-level explanation of how Regimex's effect compares to placebo in clinical trials?

Clinical trial summaries indicate that adult subjects with obesity who received Regimex in combination with dietary management tend to lose more weight on average than those subjects who only received a placebo (an inactive treatment) and diet management.

Q: Are the side effects of Regimex generally mild or severe?

The official safety profile covers a wide range of documented effects. It lists common adverse reactions such as headache and dry mouth, but it also includes warnings about the potential for rare but very serious risks, such as Primary Pulmonary Hypertension (PPH) and severe Valvular Heart Disease.

Q: What is the core difference between the purpose of Regimex and the purpose of a supplement?

Regimex is fundamentally different from a supplement because it is a Schedule III prescription drug approved by the FDA as an anorectic agent for the medical management of exogenous obesity. Supplements are defined differently and are not regulated as prescription drugs for treating medical conditions.

How to Store and Dispose of Regimex

Regimex tablets must be stored according to specific regulatory conditions to ensure product stability and safety.

Labeled Storage Conditions

Condition	Requirement
Temperature	Store below 30 C (86 F).
Protection	Store in the original package to protect from moisture.
Shelf-Life	Maintains stability for 2 years when stored under these conditions.

Security and Disposal

Due to its classification as a controlled substance, the medication must be stored locked up and strictly kept out of the reach of children.

The official labeling states that there are no special requirements for disposal of the unused product. Disposal should follow regional regulations. Authorities recommend using a drug take-back program for unused or expired tablets. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance and placed in a sealed container before being thrown in the household trash.